Alzheimer's Disease Trial, Recruiting NCT06484244 Sponsor: Emory University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06484244
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been formally diagnosed with Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI) by a qualified neurologist
  • Your MCI mainly affects memory, either noticed by you or by someone close to you
  • Your memory has been tested and shown to be below the expected level for your education background
  • Your score on a standard mental ability test (called the MMSE) is between 20 and 26 out of 30 (some exceptions may be made for people with fewer than 8 years of schooling)
  • Your level of cognitive impairment falls within a specific mild range on a standard rating scale (CDR score of 0.5)
  • You are still largely able to carry out everyday activities on your own
  • Your score on another thinking and memory test (called the MoCA) is between 13 and 17, suggesting some difficulty with planning and problem-solving
  • You are able to walk at least 10 feet without using a walking aid such as a cane or walker
  • You completed at least 6 years of schooling, or have a work history that suggests no pre-existing intellectual disability
  • You have not been admitted to a hospital in the last 60 days

Who may not be able to join:

  • You are currently dealing with a serious illness that requires a hospital stay
  • You have heart failure that is not well managed or controlled
  • You have had a stroke at any point in the past
  • You are unable to take part in the study activities for any reason
  • You have a physical condition that would prevent you from walking or taking part, such as severe arthritis, serious joint or movement problems, poorly controlled high blood pressure or diabetes, kidney failure, or chest pain triggered by physical activity
  • You are currently taking certain medications that may affect thinking or memory, such as antipsychotics, strong pain medications (opioids), stimulants, chemotherapy drugs, medications for Parkinson's disease (such as Levodopa), or medications used to treat Multiple Sclerosis or Parkinson's disease
  • You have a condition involving a break from reality, such as psychosis
  • You have another brain or nervous system condition that could affect the results, such as active brain infections, epilepsy/seizures, a serious head injury involving unconsciousness for more than 30 minutes, a brain tumour, or a stroke that caused lasting neurological or psychiatric effects
  • You have had a substance use disorder, major depression, or generalised anxiety disorder within the last 6 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Trisha Kesar, PT, PhD, Emory University

Phone: (404) 712-5803

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
22 July 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Adaptation Magnitude Assessed as Peak Step Length Symmetry; Change in Adaptation Rate Assessed as the Number of Steps to Reach Step Symmetry; Change in 10-Meter Overground Walk Test; Change in 6-Minute Walk Test; Change in Montreal Cognitive Assessment (MoCA) Score; Change in NIH-EXAMINER n-back Task Accuracy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov